gdhcer038-13-uveitis - epidemiology forecast to 2022 ...uveitis is a serious eye condition that...

REFERENCE CODE GDHCER038 | PUBLICAT ION DATE SEPTEMBER 2013

UVEITIS - EPIDEMIOLOGY FORECAST TO 2022

Uveitis - Epidemiology Forecast to 2022 2 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.

Executive Summary


Uveitis is a serious eye condition that often results

in permanent vision damage due to frequent

recurrence even after treatment. It consists of a

group of diseases that present with inflammation of

the uvea, can occur in one or both eyes, and may

also affect the adjacent tissues such as the retina,

optic nerve, and vitreous humor. The global annual

incidence of uveitis is between 17 cases per

100,000 population in Switzerland and 52 cases

per 100,000 population in the US, whereas the

prevalence is between 38 cases per 100,000

population in France and 714 cases per 100,000

population in India (Miserocchi et al., 2013).

This report provides an overview of the risk factors,

comorbidities and the global epidemiological trends

for uveitis in the six major markets (6MM: US,

France, Germany, Italy, Spain, and UK). The report

also includes a 10-year forecast of incident and

prevalent cases of uveitis segmented by age, sex,

primary anatomical location of inflammation

(anterior, intermediate, posterior, panuveitis), and

by etiology (infectious, non-infectious, idiopathic).

Incident cases are further segmented by course of

disease (acute, recurrent, chronic) and by severity

(mild, moderate, severe).

The figures below present forecast incident and

prevalent cases of uveitis in the 6MM.In 2012, the

6MM had 223,559 incident cases of uveitis, 75% of

which (168,264 cases) occurred in the US. Incident

cases in the 6MM are expected to increase slightly

to 245,353 cases by 2022, at the rate of 0.97% per

year. In 2012, the 6MM had 665,778 prevalent

cases of uveitis, which will increase to 730,913

cases in 2022 at the rate of 0.98% per year. The

US also had the largest proportion of prevalent

cases in 2012 (53.69%, 357,483 cases) out of all

markets covered in this analysis. The forecast

further shows anterior uveitis is the most common

form of uveitis and non-infectious uveitis is the

most common etiology among the 6MM.

This forecast provides detailed, granular, and

clinically relevant segmentations of uveitis cases.

The segmentations will allow for improved

understanding of the disease and the ability to

focus on specific subgroups within the disease.

The analysis is further strengthened by the

adherence to the standard clinical reporting

guidelines from the International Uveitis Study

Group (IUSG) and Standardization of Uveitis

Nomenclature (SUN) Working Group. Using

standard guidelines across the 6MM allows for

meaningful comparisons across the markets and

ensures these results will be relevant in reference

to future studies, as the use of the guidelines are

becoming more common in epidemiological

research.



Executive Summary

6MM, Incident Cases of Uveitis, N, 2012 and 2022

8,941

8,482

11,364

11,842

14,666

55,295

168,264

223,559

9,123

9,128

11,962

12,320

14,400

56,933

188,420

245,353

0 50,000 100,000 150,000 200,000 250,000

Italy

Spain

UK

France

Germany

5EU

US

6MM

Incident Cases of Uveitis (N)

Mar

kets

2022

2012

Source: GlobalData; Barisani-Asenbauer et al., 2012; Cimino et al., 2010; Gritz and Wong, 2004; Jakob et al., 2009; Mercanti et al., 2001; Päivönsalo-Hietanen et al., 1997; Pivetti-Pezzi et al., 1996; Smit et al., 1993; Tran et al., 1995; USCB, 2012. Note: 5EU = France, Germany, Italy, Spain, and UK; 6MM = 5EU, US.

6MM, Prevalent Cases of Uveitis, N, 2012 and 2022

44,819

57,888

60,613

61,805

83,170

308,295

357,483

665,778

50,710

62,459

65,351

65,916

84,455

328,891

402,022

730,913

0 200,000 400,000 600,000

Spain

UK

France

Italy

Germany

5EU

US

6MM

Prevalent Cases of Uveitis (N)

Mar

kets

2022

2012

Source: GlobalData; Cooper et al., 2009; Eaton et al., 2007; Gritz and Wong, 2004; Päivönsalo-Hietanen et al., 1997; USCB, 2012; Vadot et al., 1984. 5EU = France, Germany, Italy, Spain, and UK; 6MM = 5EU, US.



Table of Contents

1 Table of Contents

1 Table of Contents .......................................................................................................................... 4

1.1 List of Tables............................................................................................................................ 7

1.2 List of Figures .......................................................................................................................... 8

2 Introduction ................................................................................................................................... 9

2.1 Catalyst .................................................................................................................................... 9

2.2 Related Reports ..................................................................................................................... 10

2.3 Upcoming Reports ................................................................................................................. 10

3 Epidemiology ............................................................................................................................... 11

3.1 Disease Background .............................................................................................................. 11

3.2 Risk Factors and Comorbidities.............................................................................................. 12

3.2.1 Smoking increases risk of uveitis and increases complications ....................................... 12

3.2.2 Juvenile idiopathic arthritis patients need regular ophthalmologic screenings ................. 13

3.2.3 HLA-positive antigens are linked to certain types of uveitis ............................................. 14

3.2.4 Uveitis is associated with various autoimmune, neurological, and infectious diseases .... 14

3.3 Global Trends ........................................................................................................................ 16

3.3.1 US .................................................................................................................................. 18

3.3.2 5EU ................................................................................................................................ 21

3.4 Forecast Methodology ............................................................................................................ 23

3.4.1 Sources Used ................................................................................................................. 26

3.4.2 Sources Not Used........................................................................................................... 31

3.4.3 Forecast Assumptions and Methods, Incident Cases ...................................................... 32

3.4.4 Forecast Assumptions and Methods, Prevalent Cases ................................................... 33



Table of Contents

3.4.5 Forecast Assumptions and Methods, Etiological and Anatomical Distribution ................. 34

3.4.6 Forecast Assumptions and Methods, Course of Disease ................................................ 37

3.4.7 Forecast Assumptions and Methods, Disease Severity .................................................. 38

3.5 Epidemiological Forecast of Uveitis (2012–2022) ................................................................... 38

3.5.1 Incident Cases of Uveitis ................................................................................................ 38

3.5.2 Age-Specific Incident Cases of Uveitis ............................................................................ 40

3.5.3 Sex-Specific Incident Cases ........................................................................................... 42

3.5.4 Age-Standardized Incidence Rates ................................................................................. 43

3.5.5 Incident Cases by Anatomical Location .......................................................................... 44

3.5.6 Incident Cases Segmented by Etiology ........................................................................... 46

3.5.7 Course of Disease of Incident Uveitis Cases .................................................................. 49

3.5.8 Severity of Incident Uveitis Cases ................................................................................... 51

3.5.9 Prevalent Cases of Uveitis .............................................................................................. 52

3.5.10 Age-Specific Prevalent Cases of Uveitis ......................................................................... 54

3.5.11 Sex-Specific Prevalent Cases of Uveitis ......................................................................... 55

3.5.12 Prevalent Cases by Anatomical Location ........................................................................ 57

3.5.13 Prevalent Cases by Etiology ........................................................................................... 58

3.6 Discussion ............................................................................................................................. 60

3.6.1 Epidemiological Forecast Insight .................................................................................... 60

3.6.2 Limitations of the Analysis .............................................................................................. 60

3.6.3 Strengths of the Analysis ................................................................................................ 62

4 Appendix ..................................................................................................................................... 63

4.1 Bibliography ........................................................................................................................... 63



Table of Contents

4.2 About the Authors .................................................................................................................. 68

4.2.1 Epidemiologists .............................................................................................................. 68

4.2.2 Reviewers ....................................................................................................................... 68

4.2.3 Global Director of Epidemiology and Health Policy ......................................................... 70

4.2.4 Global Head of Healthcare .............................................................................................. 70

4.3 About GlobalData ................................................................................................................... 71

4.4 About EpiCast ........................................................................................................................ 71

4.5 Disclaimer .............................................................................................................................. 72



Table of Contents

1.1 List of Tables

Table 1: Diseases Most Frequently Associated with Uveitis ....................................................................... 15

Table 2: Distribution of Uveitis by Anatomical Location in Community and Referral Centers ....................... 21

Table 3: Distribution of Uveitis Cases by Anatomical Location of Inflammation, Europe .............................. 23

Table 4: IUSG/SUN Working Group Classification of Uveitis by Anatomical Location ................................. 24

Table 5: Clinical Classifications of Uveitis .................................................................................................. 24

Table 6: 6MM, Sources of Incidence and Prevalence of Uveitis in the 6MM ............................................... 25

Table 7: Italy, Anatomy Classification Calculation ...................................................................................... 35

Table 8: US, Anatomical Locations of Uveitis for Incident and Prevalent Cases .......................................... 37

Table 9: 6MM, Incident Cases of Uveitis, N (Column %), Select Years 2012–2022..................................... 39

Table 10: 6MM, Age-Specific Incident Cases of Uveitis, N (Row %), 2012 ................................................... 40

Table 11: 6MM, Sex-Specific Incident Cases of Uveitis, N (Row %), 2012.................................................... 42

Table 12: 6MM, Incident Cases of Uveitis by Primary Anatomical Location of Inflammation, N (Row %),

2012 ............................................................................................................................................ 45

Table 13: 6MM, Incident Cases of Uveitis Segmented by Etiology and Age, N (Column %), 2012 ................ 47

Table 14: 6MM, Incident Cases of Uveitis Segmented by Etiology and Anatomical Location, N, 2012 .......... 48

Table 15: 6MM, Incident Cases of Uveitis by Course of Disease, N (Row %), 2012 ...................................... 49

Table 16: 6MM, Incident Cases of Uveitis by Severity of Disease, N, 2012 ................................................... 51

Table 17: 6MM, Prevalent Cases of Uveitis, N (Column %), Select Years, 2012–2022 ................................. 53

Table 18: 6MM, Age-Specific Prevalent Cases of Uveitis, N (Row %), 2012 ................................................. 54

Table 19: 6MM, Sex-Specific Prevalent Cases of Uveitis, N (Row %), 2012 ................................................. 56

Table 20: 6MM, Prevalent Cases of Uveitis by Anatomical Location of Inflammation, N (Row %), 2012 ........ 57

Table 21: 6MM, Prevalent Cases of Uveitis Segmented by Etiology and Age, N (Column %), 2012 .............. 58

Table 22: 6MM, Prevalent Cases of Uveitis Segmented by Etiology and Anatomical Location, 2012 ............ 59



Table of Contents

1.2 List of Figures

Figure 1: US, Age Distribution of Study Populations Compared with the US General Population ................. 19

Figure 2: US, Sex-Ratio of Study Populations Compared with the US General Population ........................... 20

Figure 3: 6MM, Incident Cases of Uveitis, N, 2012–2022 ............................................................................ 39

Figure 4: 6MM, Age-Specific Incident Cases of Uveitis, N, 2012 .................................................................. 41

Figure 5: 6MM, Sex-Specific Incident Cases of Uveitis, N, 2012 .................................................................. 43

Figure 6: 6MM, Age-Standardized Uveitis Incidence, Cases per 100,000 Population, Men and Women,

2012 ............................................................................................................................................ 44

Figure 7: 6MM, Incident Cases of Uveitis by Primary Anatomical Location of Inflammation, N, 2012 ............ 46

Figure 8: 6MM, Incident Cases of Uveitis by Course of Disease, N, 2012 .................................................... 50

Figure 9: 6MM, Incident Cases of Uveitis by Severity of Disease, N, 2012 ................................................... 52

Figure 10: 6MM, Prevalent Cases of Uveitis, N, 2012–2022 .......................................................................... 53

Figure 11: 6MM, Age-Specific Prevalent Cases of Uveitis, N, 2012 ............................................................... 55

Figure 12: 6MM, Sex-Specific Prevalent Cases of Uveitis, N, 2012 ............................................................... 56



Introduction

2 Introduction

2.1 Catalyst

Uveitis is a serious eye condition that often results in permanent vision damage due to frequent

recurrence even after treatment. The global annual incidence of uveitis is between 17 cases per

100,000 population in Switzerland and 52 cases per 100,000 population in the US, whereas the

prevalence is between 38 cases per 100,000 population in France and 714 cases per 100,000

population in India (Miserocchi et al., 2013). Uveitis epidemiology warrants thorough analysis, as

recent studies have found incidence and prevalence rates that are significantly higher than

previously believed, especially in the elderly population.

This report provides an overview of the risk factors, comorbidities, and the global

epidemiological trends for uveitis in the six major markets (6MM: US, France, Germany, Italy,

Spain, and UK). In addition, the report also includes a 10-year forecast of incident and

prevalent cases of uveitis segmented by age, sex, primary anatomical location of inflammation

(anterior, intermediate, posterior, panuveitis), and by etiology (infectious, non-infectious,

idiopathic). Incident cases are further segmented by course of disease (acute, recurrent,

chronic) and by severity (mild, moderate, severe).

GlobalData epidemiologists used standardized clinical guidelines from the International Uveitis

Study Group (IUSG) and the Standardization of Uveitis Nomenclature (SUN) Working Group to

construct the epidemiologic forecast.

GlobalData epidemiologists forecast that the 6MM had 223,559 incident and 665,778 prevalent

cases of uveitis in 2012. The US had significantly higher numbers of incident and prevalent

cases than the European markets.

The forecast shows that anterior uveitis is the most common form of uveitis, and non-infectious

uveitis is the most common etiology among the 6MM.

More population-based epidemiological studies are needed to elucidate the cause of observed

high incidence and prevalence rates. Studies of temporal trends of uveitis in different

populations are also urgently needed.



Introduction

2.2 Related Reports

GlobalData (2013). OpportunityAnalyzer – Uveitis

2.3 Upcoming Reports

GlobalData (2013). EpiCast Report: Breast Cancer Epidemiology Forecast to 2022



Appendix

4.3 About GlobalData

GlobalData is a leading global provider of business intelligence in the Healthcare industry.

GlobalData provides its clients with up-to-date information and analysis on the latest developments

in drug research, disease analysis, and clinical research and development. Our integrated business

intelligence solutions include a range of interactive online databases, analytical tools, reports and

forecasts. Our analysis is supported by a 24/7 client support and analyst team.

GlobalData has offices in New York, Boston, London, India and Singapore.

4.4 About EpiCast

EpiCast is a series of premier epidemiology reports written and developed by Masters

and PhD level epidemiologists.

EpiCast Reports are in-depth, high quality, transparent and market-driven, providing expert

analysis of epidemiological trends and forecasting of patient populations for major markets.

Specifically, the reports identify disease trends over a 10-year forecast period in six to seven major

markets (US, France, Germany, Italy, Spain, UK, Japan). Additional countries, such as Canada,

Brazil, India and China, are covered in these reports if their markets are highly relevant.

tskrishna

Text Box



Appendix

4.5 Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any

form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior

permission of the publisher, GlobalData.

gdhcer038-13-uveitis - epidemiology forecast to 2022 ...uveitis is a serious eye condition that...

Documents